ArticleBlood advances2024
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes.
Erratum issuedAbstract read
In one paragraph
Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Integration of an anellovirus genome in the SKNO-1 acute myeloid leukemia cell line.Microbiology spectrum · 2026Article
- Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia.Blood cancer discovery · 2026Article
- Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.Blood · 2025Article
- Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities.Leukemia · 2025Review
- Metabolism in hematology: Technological advances open new perspectives on disease biology and treatment.HemaSphere · 2025Review
- Unraveling lipid metabolism for acute myeloid leukemia therapy.Current opinion in hematology · 2025Review
- Targeting ceramide transfer protein sensitizes AML to FLT3 inhibitors via a GRP78-ATF6-CHOP axis.Nature communications · 2025Article
- Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.Current oncology (Toronto, Ont.) · 2024Review
- The Role of Ceramide and Sphingolipid Metabolism in Cancer Therapeutics.Journal of oncology research and therapy · 2024Article
Corrections and comments
- Erratum issued
- Update of
Authors and funding
22 authors.
B Bishal PaudelDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.ORCID 0000-0002-5426-7048
Su-Fern TanDepartment of Medicine, Division of Hematology & Oncology, University of Virginia, Charlottesville, VA.ORCID 0000-0002-8301-0823
Todd E FoxDepartment of Pharmacology, University of Virginia, Charlottesville, VA.
Johnson UngDepartment of Medicine, Division of Hematology & Oncology, University of Virginia, Charlottesville, VA.ORCID 0000-0002-3275-0530
Upendarrao GollaDepartment of Medicine, Division of Hematology and Oncology, Pennsylvania State University College of Medicine, Hershey, PA.ORCID 0000-0003-0519-7087
Jeremy J P ShawDepartment of Medicine, Division of Hematology & Oncology, University of Virginia, Charlottesville, VA.
Wendy DuntonDepartment of Medicine, Division of Hematology & Oncology, University of Virginia, Charlottesville, VA.
Irene LeeDepartment of Medicine, Division of Hematology & Oncology, University of Virginia, Charlottesville, VA.
Wisam A FaresDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.
Satyam PatelDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA.ORCID 0000-0003-1578-2749
Arati SharmaDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA.
Aaron D VinyDepartment of Medicine, Division of Hematology & Oncology, and of Genetics & Development, Herbert Irving Comprehensive Cancer Center, New York, NY.ORCID 0000-0001-7039-0110
Brian M BarthDepartment of Chemistry, Biology, and Health Sciences, South Dakota School of Mines and Technology, Rapid City, SD.ORCID 0000-0002-3542-1804
Martin S TallmanRobert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
Myles CabotDepartment of Biochemistry & Molecular Biology, East Carolina University, Greenville, NC.
Francine E Garrett-BakelmanDepartment of Medicine, Division of Hematology & Oncology, University of Virginia, Charlottesville, VA.ORCID 0000-0002-4771-628X
Ross L LevineHuman Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Mark KesterDepartment of Pharmacology, University of Virginia, Charlottesville, VA.
David J FeithDepartment of Medicine, Division of Hematology & Oncology, University of Virginia, Charlottesville, VA.
David ClaxtonDepartment of Medicine, Division of Hematology and Oncology, Pennsylvania State University College of Medicine, Hershey, PA.ORCID 0000-0001-9209-2405
Kevin A JanesDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA.ORCID 0000-0002-8028-6138
Thomas P LoughranDepartment of Medicine, Division of Hematology & Oncology, University of Virginia, Charlottesville, VA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MWomen's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1MTissue Repository and Animal Models CoreP01CA171983 · NCI · UNIVERSITY OF VIRGINIA · PI JANES, KEVIN A · 2013 to 2024
$19.9MCancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9MSynergistic role of signaling and epigenetics in leukemic transformationR35CA197594 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ross L Levine · 2017 to 2026
$11.4MRole of the Cohesin complex in normal and malignant hematopoiesisK08CA215317 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VINY, AARON D · 2018 to 2022
$1.3MCombinatorial Decitabine and Liposomal Ceramide for Acute Myeloid LeukemiaR03CA252825 · NCI · UNIVERSITY OF NEW HAMPSHIRE · PI BARTH, BRIAN MICHAEL · 2020 to 2020
$151kMechanisms and In Vivo Efficacy of Synergistic Acid Ceramidase and Bcl-2 Inhibition in Acute Myeloid LeukemiaF99CA284252 · NCI · UNIVERSITY OF VIRGINIA · PI UNG, JOHNSON · 2023 to 2024
$76kTargeting Acid Ceramidase and Bcl-2 in Acute Myeloid LeukemiaF31CA271809 · NCI · UNIVERSITY OF VIRGINIA · PI UNG, JOHNSON · 2022 to 2023
$46kNCI NIH HHS F31 CA271809NCI NIH HHS F99 CA284252NCI NIH HHS K08 CA215317NCI NIH HHS P01 CA171983NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA044579NCI NIH HHS R03 CA252825NCI NIH HHS R35 CA197594NCI NIH HHS T32 CA009109
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteHumansNucleophosminNucleophosmin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.